AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02045056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Study NCT02045056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03186261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano silver fluoride solution
Description: Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.
Study NCT03186261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cavity Cleanser
Description: Moistens dentin surface after cavity preparation using a micro brush.
Study NCT03581682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-Clinic Visits Using Parent-Acquired Echos
Description: Every patient will have a tele-visit and an on-site clinic visit 1 day apart 3-6 months after the training session. Parents will have a 1-hour hands-on training session to acquire basic echo images on their children with the same hand-held device that they will use during the tele-visit. The parents will also have an in-service on how to take weight, height, and blood pressure measurements, and how to use the digital stethoscope.~A tele-visit will be schedule a day prior to the patient's regularly scheduled clinic visit. Tele-visit elements will include interim medical history by the parent and patient, and weight, height, vital signs, digital cardiac auscultation, and home echo, all obtained by the parent. Two MFS physicians, following our routine MFS care protocol, will administer either the tele-visit or on-site clinic visit, masked to the findings of the other.
Study NCT00431496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Cinacalcet tablets
Study NCT04213118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib 12mg QD PO d1-14, 21 days per cycle.
Study NCT04213118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE first, followed by anlotinib within day4（+/-1days）
Study NCT03872193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Virtual Reality Exercies
Study NCT03061812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine
Description: Powder for solution for infusion in vials.
Study NCT03061812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Powder or solution for infusion in vials. Topotecan is commercially available as both a powder and solution for infusion. Availability will vary by region.
Study NCT03061812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral tablet.
Study NCT04681924 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet intervention
Description: Low carb diet group are compared to low fat diet group and followed up for 6 months
Study NCT00751907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 40mg daily for 4 months
Study NCT00751907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo daily for 4 months
Study NCT02140723 — intervention group
Intervention type: RADIATION
Intervention: preoperative short course radiation
Study NCT05134246 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid endarterectomy (CEA)
Description: Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will receive 100 mg of aspirin or 75 mg of clopidogrel daily starting from at least 72 h prior to the CEA procedure and continued receiving the medication indefinitely. General anesthesia is recommended for CEA, although the use of standard or eversion endarterectomy, and a shunt or patch, is left to the discretion of the surgeon.
Study NCT05134246 — intervention group
Intervention type: PROCEDURE
Intervention: Carotid artery stenting (CAS)
Description: Surgeons follow the contemporary guideline combined with their experience and preference in order to ultimately select what is best suited for the patient and choose between CEA and CAS. Patients will be given 100 mg of aspirin plus 75 mg of clopidogrel daily for at least 3 days before the CAS procedure and for 90 days after the procedure. They will receive a daily dose of 100 mg aspirin or 75 mg clopidogrel thereafter. For the CAS procedure, local anaesthesia and predilation prior to stent placement are recommended. Use of an embolic protection device is mandatory for all patients who undergo CAS.
Study NCT02390349 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02390349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curamin
Study NCT02390349 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CuraMed
Study NCT00325130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Adacel™
Description: A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
Study NCT04124094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product (Fluticasone propionate and salmeterol xinafoate inhalation powder/Respirent Pharmaceuticals)
Description: Fluticasone propionate 100 mcg and salmeterol xinafoate 50 mcg inhalation powder/Respirent Pharmaceuticals
Study NCT01146548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLUOXETINE
Description: 20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.
Study NCT03136042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy techniques
Description: oscillating positive expiratory pressure during nonstop 5 minutes. After that more five minutes to a forced expiratory technique
Study NCT03136042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline 3%
Description: four nebulizations with 3% hypertonic saline, the aerosol was generated by an ultrasonic nebulizer
Study NCT04124094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product (SERETIDE DISKUS® 100/50 inhalation powder/GSK)
Description: 2 inhalations in one study period
Study NCT04124094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activated Charcoal suspension
Description: oral suspension before and after inhalation of study Investigational Products
Study NCT04124094 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activated Charcoal suspension
Description: oral suspension before and after inhalation of study Investigational Products
Study NCT05152030 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Traditional Chinese version of the University of Pennsylvania of Smell Identification Test (UPSIT-TC)
Description: The University of Pennsylvania Smell Identification Test (UPSIT), which was developed at the University of Pennsylvania, is one of the most reliable and the most widely used olfactory test.The test consists of four 10-odorant booklets. Each odorant is embedded in 10 to 50 µm urea-formaldehyde polymer microencapsules fixed in a proprietary binder and positioned on a brown strip which is located at the bottom of each page of the test booklet.4 When the examinee takes the test, each of the 40 odorants is released by scratching the strip with a pencil tip. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors.
Study NCT01332903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] AZD5069
Description: Single 120 mg oral dose administered on Day 1
Study NCT03136042 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline + physiotherapy maneuvers
Description: sputum induction by hypertonic saline at 3% for seven minutes. And more five minutes under physiotherapists maneuvers
Study NCT03336905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity program and prevention after cancer
Description: Providing a supervised and non-supervised physical activity program for adolescent and Young adult with cancer and improve awareness on cancer prevention recommendations (second cancer risk, healthy lifestyles...)
Study NCT01761487 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gentamicin and polymyxin E
Study NCT04649996 — intervention group
Intervention type: PROCEDURE
Intervention: Appendectomy
Description: comparison between operative and conservative treatment
Study NCT02613663 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implants with nanobone graft
Description: Extraction of unrestorable tooth replaced with immediate implant and use nanobone graft to fill the gap.
Study NCT03394885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200mg IV q3weeks
Study NCT03533543 — intervention group
Intervention type: DEVICE
Intervention: CEM
Description: All patients with MI hospitalized in the CCU department of Shanghai Tenth People's Hospital will receive 24-hour cardiac monitoring until discharge.
Study NCT02784431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour Neurovascular System placement
Description: Patients who meet the eligibility criteria will have their target aneurysm treated with the Contour Neurovascular System device via standard endovascular procedure.
Study NCT00873574 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood samples and buccal swabs
Description: Peripheral blood samples (35 ml) and buccal swabs
Study NCT02613663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implants with autogenous bone graft
Description: Extraction of unrestorable tooth replaced with immediate implant and use autogenous bone graft to fill the gap.
Study NCT00593177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTH (1-34) Gel / Placebo Gel
Description: Topical dosing of gel twice daily for eight weeks.
Study NCT00593177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PTH (1-34) Gel / Placebo Gel
Description: Topical dosing of gel twice daily for eight weeks.
Study NCT02015481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabaletta
Study NCT02094183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: GLP-1
Study NCT02094183 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low calorie diet
Description: low calorie diet
Study NCT03394885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 5-6mg/ML IV q3 weeks
Study NCT03394885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 70-80 mg/m2 IV q1 week
Study NCT03394885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV q3 weeks
Study NCT00396786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban 5 mg once daily plus placebo enoxaparin syringe
Study NCT00396786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban 10 mg once daily plus placebo enoxaparin syringe
Study NCT00396786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban 20 mg once daily plus placebo enoxaparin syringe
Study NCT00396786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban 30 mg once daily plus placebo enoxaparin syringe
Study NCT00396786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban 40 mg once daily plus placebo enoxaparin syringe
Study NCT00396786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 40 mg once daily plus Rivaroxaban placebo tablets
Study NCT02510469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib Mesylate Tablets 500 mg qd p.o.
Study NCT04037891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rVA576
Description: 19 Patients with moderate to severe AKC. the study includes two parts: Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.~Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
Study NCT04037891 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
Study NCT01279668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: 10mg tablets, once per day for 28 days.
Study NCT01279668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets, once per day for 28 days.
Study NCT01146548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FLUOXETINE
Description: 20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.
Study NCT03355768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Intravenous administration on a 28 day cycle
Study NCT03355768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralatrexate
Description: Intravenous administration on a 28 day cycle
Study NCT01378299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Cypionate
Description: Testosterone cypionate was administered at 200 mg by intramuscular injection every 2 weeks.~DEPo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone.~Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1oxopropoxy)-, (178)-. Its molecular formula is CvH400a, and the molecular weight of 412.61.
Study NCT04154657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conductance catheter measurement
Description: biventricular parallel conductance catheter measurement at rest and stress conditions, + CMR at rest and stress
Study NCT03284021 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fractional erbium-glass 1550 nm laser
Description: The fractional erbium-glass 1550 nm laser will be applied to the previously 100 cm2 determined area of the scalp with the following parameters: 5-10 mm tip, 5-10 mJ, pulse energy 500-1500 MTZ/cm2 density, one to twopasses, static mode.
Study NCT03182153 — intervention group
Intervention type: DEVICE
Intervention: Extended Cardiac Monitoring
Description: Extended External Cardiac Monitoring
Study NCT03725293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiodynamics BioFlo Midline Catheter
Description: Placement of Angiodynamics BioFlo Midline Catheter.
Study NCT03725293 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Teleflex Arrowg+ard Blue Advanced Midline Catheter
Description: Placement of Teleflex Arrowg+ard Blue Advanced Midline Catheter.
Study NCT01410162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: tacrolimus extended release capsules vs Prograf
Study NCT03638115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VaSecure™
Description: Drug Coated PTA Balloon Catheter
Study NCT04510402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidine iodine nasal swabs
Description: Daily versus twice daily nasal application
Study NCT03012282 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed Tomography Perfusion Imaging
Description: Undergo CT perfusion sequence
Study NCT02352532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: The dry-needling treatment will consist of inserting a sterile needle into needling the prone participant's lumbar multifidus and paraspinal muscles, 1-2 times each, in regions of local tenderness to palpation and/or regions with palpable trigger points. All needling treatment will be performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm stainless steel Seirin J-type needles (Seirin, Japan). Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique.
Study NCT02352532 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: The dry-needling treatment will consist of inserting a sterile needle into needling the prone participant's lumbar multifidus and paraspinal muscles, 1-2 times each, in regions of local tenderness to palpation and/or regions with palpable trigger points. All needling treatment will be performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm stainless steel Seirin J-type needles (Seirin, Japan). Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique.
Study NCT02352532 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Needling
Description: The sham dry-needling procedure will mimic the dry needling procedures by placing a sharp object in a needling guide tube against the skin (see figure). The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in a previous study performed at AMEDDC\&S and have found it to be indistinguishable from real dry needling by the great majority of participants.
Study NCT01225172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-754807
Description: Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
Study NCT01225172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
Study NCT00537680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: Patients ≤ 45 kg/99 lbs: idebenone 450 mg/day; Patients > 45 kg/99 lbs: idebenone 900 mg/day
Study NCT00537680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients > 45 kg/99 lbs: idebenone 2250 mg/day
Study NCT00537680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.
Study NCT04406012 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block
Description: paravertebral block group
Study NCT02213549 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02213549 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ume paste and ginger powder
Study NCT05317260 — intervention group
Intervention type: DRUG
Intervention: Antiviral Agents
Description: The type of antiviral agents for the individual patient was selected by physicians based on a policy to reimburse a patient's health and comorbidity.
Study NCT05739357 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS, EEG
Description: During the carotic clamp, if cerebral oxygenation decreased for more than 12 % on the operating side from the baseline value, simple interventions as, increasing arterial blood pressure, increasing arterial carbon dioxide tension or increasing oxygen inspiration concentration will be performed.
Study NCT01901978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restrictive diet
Description: Patients will meet weekly with a registered dietician.
Study NCT03983213 — intervention group
Intervention type: PROCEDURE
Intervention: mpfl reconstruction
Description: Harvested gracilis tendon is pulled through patella and femur in anatomic position and locked with interference screw.
Study NCT02290340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo intramuscularly.
Study NCT02290340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 10 mg
Description: Participants will receive a single dose of MEDI8897 10 milligram (mg) intramuscularly.
Study NCT02290340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 25 mg
Description: Participants will receive a single dose of MEDI8897 25 mg intramuscularly.
Study NCT02290340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI8897 50 mg
Description: Participants will receive a single dose of MEDI8897 50 mg intramuscularly.
Study NCT02455388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High added sugar diet
Description: Controlled feeding study. Participants will be provided with daily coolers containing foods with high (25%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
Study NCT02455388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low added sugar diet
Description: Controlled feeding study. Participants will be provided with daily coolers containing foods with low (5%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
Study NCT03194230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: With cervical dilatator
Description: Induction of labour by cervical placement of hygroscopic dilators (Dilapan-S Hygroscopic cervical dilator )